PubMed

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.

Tonelli M, Moyé L, Sacks FM, Kiberd B, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators.

Ann Intern Med. 2003 Jan 21;138(2):98-104.PMID: 12529091 [PubMed - indexed for MEDLINE]Related articlesFree article

Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.

Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC; Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators.

Kidney Int. 2004 Sep;66(3):1123-30.PMID: 15327407 [PubMed - indexed for MEDLINE]Related articles

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.

Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators.

J Am Soc Nephrol. 2003 Jun;14(6):1605-13.PMID: 12761262 [PubMed - indexed for MEDLINE]Related articlesFree article

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A.

Ann Intern Med. 2001 May 15;134(10):931-40.PMID: 11352694 [PubMed - indexed for MEDLINE]Related articlesFree article

Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J.

Am J Kidney Dis. 2007 Mar;49(3):373-82.PMID: 17336698 [PubMed - indexed for MEDLINE]Related articles

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.

Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators.

Am Heart J. 2003 Apr;145(4):643-51.PMID: 12679760 [PubMed - indexed for MEDLINE]Related articles

Effect of pravastatin on cardiovascular events in people with chronic kidney disease.

Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M.

Circulation. 2004 Sep 21;110(12):1557-63. Epub 2004 Sep 13. Review.PMID: 15364796 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E.

Ann Intern Med. 1998 Nov 1;129(9):681-9.PMID: 9841599 [PubMed - indexed for MEDLINE]Related articlesFree article

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.PMID: 12479764 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.

Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.

Circulation. 2004 Nov 2;110(18):2809-16. Epub 2004 Oct 18.PMID: 15492322 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.

[No authors listed]

N Engl J Med. 1998 Nov 5;339(19):1349-57.PMID: 9841303 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators.

JAMA. 2001 Jul 4;286(1):64-70.PMID: 11434828 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pravastatin in people with diabetes and chronic kidney disease.

Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G.

J Am Soc Nephrol. 2005 Dec;16(12):3748-54. Epub 2005 Oct 26.PMID: 16251235 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, Letterer R, Limacher M, Moye LA, Rouleau JL, Pfeffer MA, Braunwald E.

J Am Coll Cardiol. 1998 Jul;32(1):140-6.PMID: 9669262 [PubMed - indexed for MEDLINE]Related articles

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.

Ann Intern Med. 2001 Apr 17;134(8):629-36.PMID: 11304102 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease).

Lancet. 2002 Apr 20;359(9315):1379-87. Erratum in: Lancet 2002 Nov 2;360(9343):1430. PMID: 11978335 [PubMed - indexed for MEDLINE]Related articles

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group.

N Engl J Med. 2009 Apr 2;360(14):1395-407. Epub 2009 Mar 30.PMID: 19332456 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.

Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators.

JAMA. 2007 Sep 12;298(10):1163-70. Erratum in: JAMA. 2008 Jul 9;300(2):170. PMID: 17848650 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420. PMID: 16310551 [PubMed - indexed for MEDLINE]Related articles

Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data.

Holdaas H, Fellström B, Holme I, Nyberg G, Fauchald P, Jardine A, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Weinreich T, Olsson AG, Pedersen TR, Benghozi R, Hartmann A; ALERT Study Group. Assessment of Lescol in Renal Transplantation.

J Cardiovasc Risk. 2001 Apr;8(2):63-71.PMID: 11324372 [PubMed - indexed for MEDLINE]Related articles